A Look At Immunovant (IMVT) Valuation After Batoclimab Phase 3 Failure And Refocus On IMVT-1402

Immunovant (IMVT) is back in focus after reporting that two Phase 3 studies of batoclimab in thyroid eye disease did not meet their primary endpoint, prompting a shift in attention toward its IMVT-1402 program.

See our latest analysis for Immunovant.

Despite the batoclimab setback, Immunovant’s recent 1-day and 7-day share price returns of 1.59% and 5.69% suggest some near term optimism. Its 72.97% 1-year total shareholder return keeps the longer term story firmly in focus.

If you are tracking Immunovant’s pipeline news and want to see what else is moving in biotech, this is a good moment to check out 37 healthcare AI stocks.

With the stock at $24.89, a 1 year total return of 72.97% and analysts’ average target sitting higher at $40.12, you need to ask: is Immunovant still mispriced, or are markets already baking in future growth?

Most Popular Narrative: 39.5% Undervalued

Immunovant’s widely followed narrative pegs fair value at $41.13, compared with the last close at $24.89, putting a spotlight on what assumptions sit underneath that gap.

The fully enrolled D2T RA study for IMVT-1402, upsized to 170 patients, reflects strong physician and patient engagement that could support broader adoption in difficult to treat autoimmune populations over time, which would be most visible in revenue growth if late stage data are supportive.

Read the complete narrative.

Want to see what kind of revenue ramp and profit margins are being baked in here? The narrative leans on long dated sales forecasts, rising profitability and a rich future earnings multiple that is far from typical. Curious which numbers have to line up for $41.13 to make sense?

Result: Fair Value of $41.13 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, you also need to weigh the risk that setbacks in the IMVT-1402 trial, or higher than expected share dilution, could undercut the earnings and P/E assumptions behind $41.13.

Find out about the key risks to this Immunovant narrative.

Next Steps

Given all this, do you feel the market is too cautious or still optimistic on Immunovant, and are you ready to stress test that view using the company’s 3 important warning signs?

Looking for more investment ideas?

If Immunovant has your attention, do not stop here. Use this momentum to scan the market for other angles your future self will thank you for.

• Target strong cash generators by reviewing companies flagged in the 62 high quality undervalued stocks that pair quality fundamentals with prices that may not fully reflect them.
• Prioritize resilience by checking stocks in the 68 resilient stocks with low risk scores that score well on stability, financial strength, and downside protection.
• Hunt for future standouts by searching the screener containing 25 high quality undiscovered gems where smaller, less followed companies match up with solid underlying metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com